PARI Pharma GmbH Revenue and Competitors
Estimated Revenue & Valuation
- PARI Pharma GmbH's estimated annual revenue is currently $19.1M per year.
- PARI Pharma GmbH's estimated revenue per employee is $251,000
Employee Data
- PARI Pharma GmbH has 76 Employees.
- PARI Pharma GmbH grew their employee count by -8% last year.
PARI Pharma GmbH's People
| Name | Title | Email/Phone |
|---|
PARI Pharma GmbH Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $6.1M | 49 | -18% | $10M | N/A |
#2 | $30.4M | 121 | 29% | N/A | N/A |
#3 | $139.8M | 913 | -3% | $200K | N/A |
#4 | $84.1M | 0 | N/A | $1.2M | N/A |
#5 | $43.4M | 173 | 30% | N/A | N/A |
#6 | $64.5M | 257 | 12% | N/A | N/A |
#7 | $64.3M | 205 | 26% | $129.6M | N/A |
#8 | $19.6M | 78 | -7% | N/A | N/A |
#9 | $65.8M | 262 | 7% | N/A | N/A |
#10 | $73.7M | 235 | 20% | $115.5M | N/A |
What Is PARI Pharma GmbH?
PARI Pharma GmbH is a medical devices company based out of STEINERSTRASSE 15A, Munich, Germany.
keywords:N/AN/A
Total Funding
76
Number of Employees
$19.1M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PARI Pharma GmbH News
2022-04-17 - Savara Announces Debt Refinancing of $26.5M Credit Facility ...
Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience...
2022-03-30 - Savara Reports Fourth Quarter / Year-End 2021 Financial ...
Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience...
2022-03-22 - Insmed to Showcase New Data Across Three Pillars at the American Thoracic
Society 2022 International Conference
ARIKAYCE is administered once daily using the Lamira® Nebulizer System manufactured by PARI Pharma GmbH (PARI). About PARI Pharma and the...
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.7M | 76 | 111% | N/A |
#2 | $12.3M | 77 | 48% | N/A |
#3 | $16.9M | 77 | 71% | N/A |
#4 | $10.8M | 77 | 28% | $14M |
#5 | $12.3M | 77 | 54% | $20M |
